• Age ≥18 years

• ECOG 0-1

• Histologically confirmed intrahepatic cholangiocarcinoma (also variously reported as peripheral cholangiocarcinoma, cholangiolar carcinoma or cholangiocellular carcinoma) (IHC). Confirmation of the diagnosis at MSKCC or at the enrolling institution must be obtained prior to randomization.

• Clinical or radiographic evidence of metastatic disease confined to the liver. Note: presence of regional (porta hepatis) lymph node metastases will be allowed, provided they are amenable to resection. (Note: If peritoneal or other extrahepatic disease is found at time of pump placement, the pump will not be implanted. The patient will be removed from study, deemed nonevaluable and will not count toward the overall study accrual.)

• Radiographically measurable disease. Measurable disease is defined as disease that can be assessed with 2-dimensional measurements on a cross-sectional imaging. Minimum lesion size is 2 cm in greatest diameter as per RECIST criteria.

• Disease must be considered unresectable at the time of preoperative evaluation.\*

• Considered candidate for general anesthesia, abdominal exploration and hepatic artery pump placement.

• Patients with chronic hepatitis and/or cirrhosis are eligible, but must be Child-Pugh class A.

• WBC ≥ 2,000/mcL , ANC ≥ 1000/mcL

• Platelet count ≥ 75,000/mcL

• Creatinine ≤ 1.8 mg/dL

• Total bilirubin \< 1.5 mg/dL

• Hgb \> 7 g/dL The % involvement of the liver will be determined by radiologists after review of imaging